通心络胶囊联合瑞舒伐他汀治疗冠心病合并心力衰竭患者的疗效及其对血管内皮功能的影响

Efficacy of Tongxinluo capsule combined with rosuvastatin on coronary heart disease complicated with heart failure and their effects on vascular endothelial function

目的观察通心络胶囊联合瑞舒伐他汀治疗冠心病合并心力衰竭患者的疗效及其对血管内皮功能的影响。方法选取2017年12月至2019年12月在我院住院治疗的冠心病合并心力衰竭患者70例为研究对象,采用随机数字法分为观察组和对照组,每组35例。对照组患者在常规治疗的基础上口服瑞舒伐他汀钙片治疗,观察组患者在对照组治疗的基础上加服通心络胶囊治疗,疗程3个月。比较两组患者的临床疗效,检测比较两组患者治疗前后左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)以及血管内皮生长因子(VEGF)、一氧化氮(NO)、内皮素(ET)、血栓素B2(TXB2)水平。结果观察组患者的治疗总有效率(94.3%)显著高于对照组(77.1%),临床疗效明显优于对照组,差异有统计学意义(P<0.05)。治疗3个月后,两组患者的LVEF均显著增高,两组患者的LVEDD、LVESD均显著降低;观察组患者的LVEF显著高于对照组,LVEDD、LVESD显著低于对照组,差异有统计学意义(P<0.05);两组患者的VEGF、NO水平均显著升高,ET、TXB2水平均显著降低;观察组患者的VEGF、NO水平显著高于对照组,ET、TXB2水平显著低于对照组,差异有统计学意义(P<0.05)。结论通心络胶囊联合瑞舒伐他汀治疗能显著改善冠心病合并心力衰竭患者的心功能及血管内皮功能,提高临床治疗效果。

Objective To observe the efficacy of Tongxinluo capsule combined with rosuvastatin in the treatment of patients with coronary heart disease complicated with heart failure and their effects on vascular endothelial function.Methods A total of 70 patients with coronary heart disease complicated with heart failure who were hospitalized in our hospital from December 2017 to December 2019 were selected as the research objects,and they were divided into observation group and control group by the random number method,with 35 cases in each group.Patients in the control group were orally administrated with rosuvastatin calcium tablets on the basis of conventional treatment,based on which patients in the observation group were additionally administrated with Tongxinluo capsules,for a three-month treatment course.The clinical efficacy was compared between the two groups,and the left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),vascular endothelial growth factor(VEGF),nitric oxide(NO),endothelin(ET),and thromboxane B2(TXB2)levels of the two groups before and after treatment were tested and compared.Results The total effective rate of treatment in the observation group(94.3%)was significantly higher than that in the control group(77.1%),and the clinical efficacy was significantly superior to that in the control group,with statistically significant differences(P<0.05).After 3 months of treatment,the LVEF increased significantly,whereas the LVEDD and LVESD decreased significantly in both groups;compared with the control group,the observation group yielded higher LVEF,whereas lower LVEDD and LVESD,with statistically significant differences(P<0.05).The levels of VEGF and NO increased significantly,and the levels of ET and TXB2 decreased significantly in both groups;compared with the control group,the observation group yielded higher levels of VEGF and NO,whereas lower levels of ET and TXB2,with statistically significant differences(P<0.05).Conclusion Tongxinluo capsule combined with rosuvastatin for treatment can significantly improve the cardiac function and vascular endothelial function of patients with coronary heart disease complicated with heart failure,and improve the clinical efficacy.